Using a rat liver fibrosis model Wang et al. showed that sorafenib, a multiple receptor tyrosine kinase inhibitor that among others targets the VEGF receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit) [40], reduces intrahepatic fibrogenesis. This evidence concerns the gene KDR and Hepatic fibrosis.